Capstone Therapeutics (CAPS) Announces Initiation Of Dosing For AEM-28 Phase 1 Human Clinical Trial In LDL/Non-HDL Cholesterol Reduction
4/8/2014 7:34:37 AM
TEMPE, Ariz., April 8, 2014 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS) ("the Company") and its joint venture affiliate, LipimetiX Development, LLC ("JV"), announced today the initiation of dosing for its AEM-28 (Apo E mimetic peptide) Phase 1 human clinical trial in LDL/non-HDL cholesterol reduction.
Help employers find you! Check out all the jobs and post your resume.
comments powered by